Published on 2020 Nov 17 PubMed Endometriosis is an often chronic, inflammatory gynaecologic condition affecting 190 million women worldwide. Studies have reported an elevated cancer risk among patients with ENDOMETRIOSIS. https://pubmed.ncbi.nlm.nih.gov/33202017/
as some suggested in here/PYC chat that Astellas Pharma Europe B.V. may be our Japanese pharma wanting not to be named, they already trialed their ASP1707 & completed , Last Update March 29, 2019
2 trials ( Recruiting & Active, not recruiting ) for ENDOMETRIOSIS treatment in Japan. 10 trials ( Completed ) 1 trial ( Completed & Has Results )
** These are the campanies on the list Kissei Pharmaceutical Co., Ltd. Bayer Mylan Inc Astellas Pharma Europe B.V. ASKA Pharmaceutical Co., Ltd. Takeda
ONLY 2 trials are Recruiting & Active, not recruiting
* Bayer`s own drug BAY86-5300 YAZ-Flex * Aska licenced TAK-385 from Takeda who already trialed it but Aska is trialing it with their on way
** Third may well be Val301 licenced from Valirx only for Japan ( I say " may be " )
AbbVie is accusing Japan's Takeda Pharmaceutical of breaching a license and supply agreement covering the prostate cancer and endometriosis drug https://www.law360.com/articles/1327172